BridgeBio Oncology Therapeutics (BBOT) Net Income towards Common Stockholders (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Net Income towards Common Stockholders of -$62.1 million for Q1 2026, up 27.96% sequentially from -$86.2 million in Q4 2025, and down 15737.55% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$62.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 15737.55% year-over-year to -$62.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$233.1 million (down 47488.79% YoY) and the FY2025 annual result came in at -$233.0 million, down 14430.74% from the prior year.
- Net Income towards Common Stockholders grew to -$62.1 million in Q1 2026 per BBOT's latest filing, from -$86.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $1.9 million in Q3 2024 and troughed at -$86.2 million in Q4 2025.
- A 3-year average of -$25.8 million and a median of -$392024.0 in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders tumbled 89.9% in 2025, then sank 15737.55% in 2026.
- Over 3 years, Net Income towards Common Stockholders stood at -$2.8 million in 2024, then sank by 3008.38% to -$86.2 million in 2025, then grew by 27.96% to -$62.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$62.1 million, -$86.2 million, and -$85.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -70.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.81 Mn |
| Mar 31, 2026 | -62.09 Mn |
| Dec 31, 2025 | -86.18 Mn |
| Sep 30, 2025 | -85.02 Mn |
| Jun 30, 2025 | 179,685.00 |
| Mar 31, 2025 | -392,024.00 |
| Dec 31, 2024 | -2.77 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 765,894.00 |